In the MYPATHWAY trial, among the initial 36 patients who received trastuzumab plus pertuzumab for tumors with HER2 mutations without amplification/overexpression, no responders were found in breast cancer.30 This evidence concerns the gene ERBB2 and breast carcinoma.